Enforcement of Patents Against Competitive Infringement Sample Clauses
The 'Enforcement of Patents Against Competitive Infringement' clause establishes the rights and obligations of parties regarding the protection and enforcement of patents when a competitor is suspected of infringing on those rights. Typically, this clause outlines the procedures for identifying potential infringement, the responsibilities for initiating legal action, and how any resulting costs or recoveries are shared between the parties. Its core practical function is to ensure that both parties are aligned in defending their intellectual property, thereby deterring competitors from unauthorized use and clarifying how enforcement actions are managed.
POPULAR SAMPLE Copied 1 times
Enforcement of Patents Against Competitive Infringement. With respect to infringement, unauthorized use, misappropriation or threatened infringement by a Third Party of any Akcea Product-Specific Patents by reason of the development, manufacture, use or commercialization of a product that binds to an Exclusive Target (“Competitive Infringement”), prior to the date Novartis exercises its applicable Option under this Agreement (or after Option exercise with respect to an Akcea Special Product-Specific Patent), Akcea will have the sole right, but not the obligation, to institute, prosecute, and control a Proceeding with respect thereto. With respect to any Competitive Infringement involving an Akcea Licensed Patent that is not an Akcea Special Product-Specific Patent that occurs after the date Novartis exercises its applicable Option under this Agreement, the Parties will handle such Competitive Infringement in accordance with the remainder of this Section 8.6.
Enforcement of Patents Against Competitive Infringement. With respect to infringement, unauthorized use, misappropriation or threatened infringement by a Third Party of any Product-Specific Patents by reason of the development, manufacture, use or commercialization of a product that binds to a Collaboration Target in the Field (“Competitive Infringement”), prior to the applicable Collaboration Program Exercise Date, Isis will have the sole right (with no obligation to discuss with AstraZeneca), but not the obligation, to institute, prosecute, and control a Proceeding with respect thereto. With respect to any Competitive Infringement after the applicable Collaboration Program Exercise Date, the Parties will handle such Competitive Infringement in accordance with the remainder of this Section 7.5.
Enforcement of Patents Against Competitive Infringement. With respect to infringement, unauthorized use, or threatened infringement or such other activity by a Third Party of any Product-Specific Patents, Jointly-Owned Program Patents, or Ionis Core Technology Patents by reason of the development, manufacture, use or commercialization of a product that is designed to bind to the RNA encoding APO(a) (“Competitive Infringement”), the Parties will handle such Competitive Infringement in accordance with this Section 8.6 (Enforcement of Patents Against Competitive Infringement).
Enforcement of Patents Against Competitive Infringement. With respect to infringement, unauthorized use, misappropriation or threatened infringement by a Third Party of any Akcea Product-Specific Patent Rights by reason of the Exploitation of a product that binds to ANGPTL3 (“Competitive Infringement”), the Parties will handle such Competitive Infringement in accordance with the remainder of this Section 9.4. 165301880
Enforcement of Patents Against Competitive Infringement. With respect to infringement, unauthorized use, misappropriation or threatened infringement by a Third Party of any Product-Specific Patent by reason of the development, manufacture, use or commercialization of a product that binds to a Collaboration Target or to [***] in the Field (“Competitive Infringement”), prior to the applicable Collaboration Program Exercise Date, or, with respect to [***], the Fourth Amendment Effective Date, Ionis will have the sole right (with no obligation to discuss with AstraZeneca), but not the obligation, to institute, prosecute, and control a Proceeding with respect thereto. With respect to any Competitive Infringement after the Fourth Amendment Effective Date, the Parties will handle such Competitive Infringement in accordance with the remainder of this Section 7.5.” t. Section 7.5.2. The first sentence of Section 7.5.2 (Control of Competitive Infringement Proceedings) is hereby deleted in its entirety and replaced with the following:
Enforcement of Patents Against Competitive Infringement